Dr. Chong is a seasoned pharmaceutical/biotech physician with over 30 years drug development experience across several therapeutic areas (cardiovascular, oncology, nephrology, endocrinology, rheumatology, immunology and transplant medicine).
Until recently, Dr. Chong was the Chief Medical Officer at Vitaeris Inc where he was responsible for re-purposing and obtaining regulatory agreement for an expedited development program of a drug for the treatment of chronic antibody mediated rejection in kidney transplant recipients, the leading cause of long-term allograft loss. He formed the development team and initiated the global phase 3 study. Vitaeris Inc was acquired by CSL Behring in 2020. Prior to Vitaeris Inc, he was the Vice President, Clinical Research at Aspreva Pharmaceuticals, and then subsequent to its sale, as Vice President responsible for global clinical research and biometrics at Vifor Pharma where he led the global clinical development team resulting in worldwide approvals of a Velphoro® for the treatment of hyperphosphatemia in patients with end stage renal failure.
He has interacted extensively with regulatory authorities (e.g., FDA, EMA) and has been involved in strategic business development and licensing activities resulting in several successful partnerships with US and Japanese companies.
Dr. Chong is a cardiologist by training and received his medical education at the Universities of Dundee and Glasgow, Scotland. He is a member of the Royal Colleges of Physicians (UK) and holds a Diploma in Pharmaceutical Medicine from its Faculty of Pharmaceutical Medicine.
